Cook R&D Goals Suggest Logic Behind $219 Mil. Deal With Baxter
This article was originally published in The Gray Sheet
Cook Group's divestiture of its Pharmaceutical Solutions unit to Baxter Healthcare for $219 mil. in cash and stock will help the privately-held firm focus on U.S. clinical trial enrollment for its Logic PTX paclitaxel-coated stent for anti-restenosis
You may also be interested in...
An upturn in M&A activity across the whole healthcare sector is expected in 2021, with the COVID-19 pandemic and the associated development of a vaccine shining a light on the sector, says a recent survey by Jefferies.
Australian patients with phototoxicity due to the rare condition EPP will now have their first treatment option – provided the drug's developer, Clinuvel, secures reimbursement under the Pharmaceutical Benefits Scheme.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.